Latest Insider Positions

Williamson Thomas P. is listed as an insider in the following companies: ENTL / Entellus Medical, Inc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.


Security Title Post Shares
ENTL / Entellus Medical VP, Commercial Operations 0

Latest Transactions

Tran Date
Security Code Shares Post Shares Percent
2018-02-28 ENTL / Entellus Medical D -44,986 0 -100.00 24 -1,079,664
2018-01-08 ENTL / Entellus Medical S -1,481 44,986 -3.19 24.12 -35,722 1,085,062 -3.29
2018-01-05 ENTL / Entellus Medical S -968 46,467 -2.04 24.01 -23,242 1,115,673 -2.08
2017-11-04 ENTL / Entellus Medical A 10,000 47,217 26.87
2017-02-04 ENTL / Entellus Medical A 20,000 37,033 117.42
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Peers of Williamson Thomas P. include the following: BAKEWELL JOHN K, BOIANO MARGARET A, BURNHAM JONELLE R, Baltzell Joshua J, Christian Martha J., ESSEX WOODLANDS HEALTH VENTURES FUND VIII LP, ESSEX WOODLANDS HEALTH VENTURES FUND VIII-A LP, ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B LP, Essex Woodlands Health Ventures VIII, L.L.C., Essex Woodlands Health Ventures VIII, L.P., Farley Brian E, GRIFFIN THOMAS E, Gonzales Donald A., INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P., INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P., INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P., KOGL JEFF L, MENSINK KEVIN L, MOMTAZEE JAMES C, McCormick Shawn, Milne David Bruce, Moen Brent, NEELS GUIDO J, PAIDOSH STEPHEN R, PETERSON KAREN E, PETRICK TIMOTHY B, Rohlen Douglas, Rosenthal Michael Harry, STRYKER CORP, SUREK JAMES D, SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P., SV LIFE SCIENCES FUND IV, L.P., SVLSF IV, LLC, Split Rock Partners Management LLC, Split Rock Partners, LP, WHITE ROBERT S., . Peers are determined by cross-linking the filings of Williamson Thomas P. with insider filings of others at the same companies.

Related News Stories

Stryker (SYK) Q1 Earnings Beat Estimates, 2018 View Solid

2018-04-27 zacks
Stryker Corporation (SYK - Free Report) reported first-quarter 2018 adjusted earnings per share (EPS) of $1.68, beating the Zacks Consensus Estimate by 5%. The EPS figure exceeded the high end of the guidance and also increased 13.5% year over year. (18-0)

Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?

2018-04-16 zacks
Stryker Corporation’s (SYK - Free Report) first-quarter 2018 results are scheduled for release on Apr 26, after market close. The company’s acquisition-driven strategy is expected to boost growth by expanding existing product offerings in all business segments. (89-1)

Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

2018-03-01 zacks
Chicago, IL – March 1, 2018 – Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Abbott (ABT - Free Report) , Becton, Dickinson and Co. (BDX - Free Report) , Stryker (SYK - Free Report) , Varian Medical (VAR - Free Report) and Boston Scientific (BSX - Free Report) . (137-0)

MedTech's Long-Term Prospects Outweigh Near-Term Risks

2018-03-01 zacks
In the past few years, the U.S. medical device market has undergone substantial transformation. While there are a number of regulatory and financial issues unlikely to be resolved soon, powerful long-term tailwinds, including mergers & acquisitions (M&As), emerging market expansion, positive demographic trends and product innovation, have been contributing to the continued growth of the sector. (126-1)

Why Stryker Will Likely Continue Delivering Strong Growth

2018-02-19 seekingalpha
The company's stock price has faltered some recently, but is still up significantly over the past 12 months. (12-0)